Wyeth Tops The Wall Street Journal Patent Scorecard

August 21, 2007
BioPharm International Editors

The August 7, 2007, issue of The Wall Street Journal Patent Scorecard ranks Wyeth (Madison, NJ, www.wyeth.com) first among 35 global pharmaceutical companies evaluated for patent-based intellectual property (IP).

The August 7, 2007, issue of The Wall Street Journal Patent Scorecard ranks Wyeth (Madison, NJ, www.wyeth.com) first among 35 global pharmaceutical companies evaluated for patent-based intellectual property (IP). Pfizer, Inc. (New York, NY, www.pfizer.com) took the second position and Johnson & Johnson (New Brunswick, NJ, www.jnj.com) was ranked third, with Bristol-Myers Squib (New York, NY, www.bms.com) and Novartis AG (Basel, Switzerland, www.novartis.com) following close behind at numbers four and five.

The indicators used for measuring patent-based IP included patents granted; quality of patents; science strength, or the degree to which a company’s patent portfolio is linked to core science; research intensity, a comparative measure of the level of basic research; and innovation cycle time.